(Q34182017)

31 July 2017

title

Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine (English)

1 reference

31 July 2017

main subject

irritable bowel syndrome

1 reference

Mauro Bafutto

1

1 reference

31 July 2017

José Roberto de Almeida

2

1 reference

31 July 2017

Nayle Vilela Leite

3

1 reference

31 July 2017

Enio Chaves Oliveira

4

1 reference

31 July 2017

Salustiano Gabriel-Neto

5

1 reference

31 July 2017

Joffre Rezende-Filho

6

1 reference

31 July 2017

publication date

1 January 2011

1 reference

Arquivos de Gastroenterologia

31 July 2017

published in

1 reference

31 July 2017

volume

48

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

36-40

1 reference

Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

New pathophysiological mechanisms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Almost all irritable bowel syndromes are post-infectious and respond to probiotics: controversial issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

The role of psychological and biological factors in postinfective gut dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Prognosis in post-infective irritable bowel syndrome: a six year follow up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Post-infectious irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Role of infection in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

10.1590/S0004-28032011000100008

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference